by ankyratx1dev | Feb 18, 2026
Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO ANK-203 is a first-in-class anchored immunotherapy designed to unlock the full therapeutic potential of monoclonal antibody...
by ankyratx1dev | Dec 15, 2025
Ankyra appoints Sailaja Battula, PhD as chief scientific officer (CSO) December 15, 2025 (Cambridge, MA) – Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced Sailaja...
by ankyratx1dev | Nov 17, 2025
Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored...
by ankyratx1dev | Nov 4, 2025
Ankyra announces publication of Phase 1 clinical data, and will present at the Society for Immunotherapy of Cancer (SITC) annual meeting Initial Phase 1 data, recently published in Nature Communications, demonstrated clinical activity with no dose limiting toxicity in...
by ankyratx1dev | Apr 28, 2025
Ankyra Therapeutics announced preliminary clinical data today from Part 1 of their Phase 1 ANCHOR study evaluating an anchored IL-12 drug conjugate, tolododekin alfa, as monotherapy in patients with solid tumors Ankyra also announced the first patient has been dosed...
